Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma

被引:44
作者
Houben, Roland
Michel, Barbara
Vetter-Kauczok, Claudia S.
Pfoehler, Claudia
Laetsch, Barbara
Wolter, Manfred D.
Leonard, J. Helen
Trefzer, Uwe
Ugurel, Selma
Schrama, David
Becker, Juergen C.
机构
[1] Univ Wurzburg, Klin & Poliklin Haut & Geschlechtskrankheiten, Wurzburg, Germany
[2] Saarland Univ Hosp, Dept Dermatol, Homburg, Germany
[3] Univ Zurich, Dermatol Klin, Zurich, Switzerland
[4] Goethe Univ Frankfurt, Dept Dermatol, D-6000 Frankfurt, Germany
[5] Queensland Inst Med Res, Queensland Radium Inst Lab, Brisbane, Qld 4006, Australia
[6] Univ Med Berlin, Dept Dermatol & Allergy, Charite, Berlin, Germany
[7] Univ Hosp Mannheim, Skin Canc Unit, German Canc Res Ctr, Dept Dermatol, Mannheim, Germany
关键词
D O I
10.1038/sj.jid.5700170
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Merkel cell carcinoma (MCC) is a highly metastatic skin tumor. To assess the relevance of the Ras/Raf/MEK/MAP kinase pathway, we analyzed for activating B-Raf mutations and we elucidated the presence of the Raf Kinase Inhibitor Protein (RKIP) and extracellular signal-regulated kinase (ERK) as well as the phosphorylation status of ERK. All MCC samples were negative for the B-Raf V600E mutation. Remarkably, RKIP, which was shown to interfere with the activation of MEK by Raf, was highly expressed in primary as well as in metastatic MCC. Immunohistochemical analysis of the phosphorylation status of ERK revealed in 42 out of 44 samples a complete lack of activated ERK in the tumor cells although ERK is expressed; in the two positive cases phosphorylated ERK was restricted to a minor fraction of the tumor cells. Western blot analysis of three MCC-derived cell lines revealed in one case the pattern present in situ (i.e. high RKIP expression and complete absence of phosphorylated ERK). In summary, our data demonstrate the inactivity of the classical MAP kinase signal transduction pathway in MCC, which seems to be because of lack of activation as well as active deactivation. These findings should be accounted for in future therapeutic approaches for this tumor.
引用
收藏
页码:1135 / 1142
页数:8
相关论文
共 46 条
[1]   The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling - Role in FTI enhancement of taxane and tamoxifen anti-tumor activity [J].
Basso, AD ;
Mirza, A ;
Liu, GJ ;
Long, BJ ;
Bishop, WR ;
Kirschmeier, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) :31101-31108
[2]  
Blackhall FH, 2003, CLIN CANCER RES, V9, P2241
[3]  
BOS JL, 1989, CANCER RES, V49, P4682
[4]  
Brose MS, 2002, CANCER RES, V62, P6997
[5]   MAP kinases [J].
Chen, Z ;
Gibson, TB ;
Robinson, F ;
Silvestro, L ;
Pearson, G ;
Xu, BE ;
Wright, A ;
Vanderbilt, C ;
Cobb, MH .
CHEMICAL REVIEWS, 2001, 101 (08) :2449-2476
[6]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[7]   Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma [J].
Davidson, B ;
Givant-Horwitz, V ;
Lazarovici, P ;
Risberg, B ;
Nesland, JM ;
Trope, CG ;
Schaefer, E ;
Reich, R .
CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (07) :621-631
[8]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[9]  
DeSilva DR, 1998, J IMMUNOL, V160, P4175
[10]   The importance of being K-Ras [J].
Ellis, CA ;
Clark, G .
CELLULAR SIGNALLING, 2000, 12 (07) :425-434